- Home
- THRD vs ZVRA Comparison
THRD vs ZVRA Comparison
Compare THRD & ZVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- THRD
- ZVRA
- Stock Information
- Founded
- THRD 2019
- ZVRA 2006
- Country
- THRD United States
- ZVRA United States
- Employees
- THRD N/A
- ZVRA N/A
- Industry
- THRD Biotechnology: Pharmaceutical Preparations
- ZVRA Biotechnology: Pharmaceutical Preparations
- Sector
- THRD Health Care
- ZVRA Health Care
- Exchange
- THRD Nasdaq
- ZVRA Nasdaq
- Market Cap
- THRD 513.2M
- ZVRA 473.6M
- IPO Year
- THRD 2022
- ZVRA 2015
- Fundamental
- Price
- THRD $11.45
- ZVRA $9.09
- Analyst Decision
- THRD Strong Buy
- ZVRA Strong Buy
- Analyst Count
- THRD 3
- ZVRA 7
- Target Price
- THRD $20.33
- ZVRA $21.20
- AVG Volume (30 Days)
- THRD 218.2K
- ZVRA 677.5K
- Earning Date
- THRD 11-07-2024
- ZVRA 11-12-2024
- Dividend Yield
- THRD N/A
- ZVRA N/A
- EPS Growth
- THRD N/A
- ZVRA N/A
- EPS
- THRD N/A
- ZVRA N/A
- Revenue
- THRD N/A
- ZVRA $24,489,000.00
- Revenue This Year
- THRD N/A
- ZVRA N/A
- Revenue Next Year
- THRD N/A
- ZVRA $318.48
- P/E Ratio
- THRD N/A
- ZVRA N/A
- Revenue Growth
- THRD N/A
- ZVRA 47.85
- 52 Week Low
- THRD $7.08
- ZVRA $4.20
- 52 Week High
- THRD $16.94
- ZVRA $9.30
- Technical
- Relative Strength Index (RSI)
- THRD 40.06
- ZVRA 59.84
- Support Level
- THRD $10.10
- ZVRA $8.32
- Resistance Level
- THRD $12.49
- ZVRA $9.27
- Average True Range (ATR)
- THRD 1.30
- ZVRA 0.53
- MACD
- THRD -0.32
- ZVRA 0.00
- Stochastic Oscillator
- THRD 25.00
- ZVRA 81.82
About THRD Third Harmonic Bio Inc.
Third Harmonic Bio Inc is a biopharmaceutical company focused on the development of the next wave of medicine for the treatment of inflammatory diseases, including dermal, respiratory, and gastrointestinal diseases. The company's product candidate, THB001, is a selective, oral small-molecule inhibitor of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival. Its other product candidate THB335, is a potent, selective, oral small molecule KIT inhibitor, for the treatment of multiple mast cell-driven inflammatory diseases of the skin, airway, and gastrointestinal tract.
About ZVRA Zevra Therapeutics Inc.
Zevra Therapeutics Inc is a rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options. The company's mission is to bring life-changing therapeutics to people living with rare diseases. With unique, data-driven development and commercialization strategies, it is overcoming complex drug development challenges to make new therapies available to the rare disease community.